The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Cytidine-2-14C     4-amino-1-[3,4-dihydroxy-5...

Synonyms: AGN-PC-006J9M, SureCN149563, SureCN6672256, MolMap_000003, ACMC-209nqw, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Aracytidine


Psychiatry related information on Aracytidine


High impact information on Aracytidine


Chemical compound and disease context of Aracytidine


Biological context of Aracytidine


Anatomical context of Aracytidine

  • Lower doses of cytarabine or hydroxyurea resulted in smaller waves of reticulocyte regeneration and lesser effects on F-reticulocyte production [20].
  • When such treatment with 1,25(OH)2D3 immediately followed a sublethal exposure to drugs that inhibit DNA synthesis, including the cancer chemotherapeutic agents cytarabine and hydroxyurea, the proportion of HL-60 cells lethally damaged was increased [21].
  • Spinal cord penetration of intrathecally administered cytarabine and methotrexate: a quantitative autoradiographic study [22].
  • Adults under the age of 55 were randomised for central nervous system (CNS) prophylaxis with intrathecal cytarabine and methotrexate [23].
  • Because the clinical effectiveness of cytarabine in the treatment of nonmalignant diseases has not been proved, its use in these disorders must be considered investigational and weighed against the serious bone-marrow suppression and potential long-term hazards of this drug [24].

Associations of Aracytidine with other chemical compounds


Gene context of Aracytidine


Analytical, diagnostic and therapeutic context of Aracytidine


  1. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. Mayer, R.J., Davis, R.B., Schiffer, C.A., Berg, D.T., Powell, B.L., Schulman, P., Omura, G.A., Moore, J.O., McIntyre, O.R., Frei, E. N. Engl. J. Med. (1994) [Pubmed]
  2. Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. Wisch, J.S., Griffin, J.D., Kufe, D.W. N. Engl. J. Med. (1983) [Pubmed]
  3. Interferon alfa-2b and cytarabine in chronic myelogenous leukemia. Patel, T., Roychowdhury, D.F. N. Engl. J. Med. (1997) [Pubmed]
  4. Loss of ras oncogene mutation in a myelodysplastic syndrome after low-dose cytarabine therapy. Layton, D.M., Mufti, G.J., Lyons, J., Janssen, J.W., Bartram, C.R. N. Engl. J. Med. (1988) [Pubmed]
  5. Therapy of secondary acute nonlymphocytic leukemia with cytarabine. Preisler, H.D., Early, A.P., Raza, A., Vlahides, G., Marinello, M.J., Stein, A.M., Browman, G. N. Engl. J. Med. (1983) [Pubmed]
  6. Acute leukemia occurring after radiotherapy and chemotherapy with a nitrosourea, PCNU. Shepard, K.V., Larson, R., Le Beau, M.M., Leichman, L., Levin, B. Investigational new drugs. (1988) [Pubmed]
  7. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. Cassileth, P.A., Harrington, D.P., Appelbaum, F.R., Lazarus, H.M., Rowe, J.M., Paietta, E., Willman, C., Hurd, D.D., Bennett, J.M., Blume, K.G., Head, D.R., Wiernik, P.H. N. Engl. J. Med. (1998) [Pubmed]
  8. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. Hall, C.D., Dafni, U., Simpson, D., Clifford, D., Wetherill, P.E., Cohen, B., McArthur, J., Hollander, H., Yainnoutsos, C., Major, E., Millar, L., Timpone, J. N. Engl. J. Med. (1998) [Pubmed]
  9. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. Guilhot, F., Chastang, C., Michallet, M., Guerci, A., Harousseau, J.L., Maloisel, F., Bouabdallah, R., Guyotat, D., Cheron, N., Nicolini, F., Abgrall, J.F., Tanzer, J. N. Engl. J. Med. (1997) [Pubmed]
  10. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. Ravindranath, Y., Yeager, A.M., Chang, M.N., Steuber, C.P., Krischer, J., Graham-Pole, J., Carroll, A., Inoue, S., Camitta, B., Weinstein, H.J. N. Engl. J. Med. (1996) [Pubmed]
  11. Acute hypereosinophilic syndrome. Successful treatment with vincristine, cytarabine, and prednisone. Van Slyck, E.J., Adamson, T.C. JAMA (1979) [Pubmed]
  12. Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine. Dougherty, J.B., Kelsen, D., Kemeny, N., Magill, G., Botet, J., Niedzwiecki, D. J. Natl. Cancer Inst. (1989) [Pubmed]
  13. Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma. McLaughlin, P., Velasquez, W.S., Redman, J.R., Yung, W.K., Hagemeister, F.B., Rodriguez, M.A., Cabanillas, F. J. Natl. Cancer Inst. (1988) [Pubmed]
  14. Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Sweet, D.L., Golomb, H.M., Ultmann, J.E., Miller, J.B., Stein, R.S., Lester, E.P., Mintz, U., Bitran, J.D., Streuli, R.A., Daly, K., Roth, N.O. Ann. Intern. Med. (1980) [Pubmed]
  15. Induction of topoisomerase I cleavage complexes by 1-beta -D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. Pourquier, P., Takebayashi, Y., Urasaki, Y., Gioffre, C., Kohlhagen, G., Pommier, Y. Proc. Natl. Acad. Sci. U.S.A. (2000) [Pubmed]
  16. Arabinosylcytosine induces fetal hemoglobin in baboons by perturbing erythroid cell differentiation kinetics. Papayannopoulou, T., Torrealba de Ron, A., Veith, R., Knitter, G., Stamatoyannopoulos, G. Science (1984) [Pubmed]
  17. Clustering of adverse drug events: analysis of risk factors for cerebellar toxicity with high-dose cytarabine. Jolson, H.M., Bosco, L., Bufton, M.G., Gerstman, B.B., Rinsler, S.S., Williams, E., Flynn, B., Simmons, W.D., Stadel, B.V., Faich, G.A. J. Natl. Cancer Inst. (1992) [Pubmed]
  18. Transcriptional regulation of c-jun gene expression by arabinofuranosylcytosine in human myeloid leukemia cells. Kharbanda, S.M., Sherman, M.L., Kufe, D.W. J. Clin. Invest. (1990) [Pubmed]
  19. Ineffectiveness of subcutaneous cytosine arabinoside in localized herpes zoster. Betts, R.F., Zaky, D.A., Douglas, R.G., Royer, G. Ann. Intern. Med. (1975) [Pubmed]
  20. Stimulation of F-cell production in patients with sickle-cell anemia treated with cytarabine or hydroxyurea. Veith, R., Galanello, R., Papayannopoulou, T., Stamatoyannopoulos, G. N. Engl. J. Med. (1985) [Pubmed]
  21. Potentiation by 1-alpha,25-dihydroxyvitamin D3 of cytotoxicity to HL-60 cells produced by cytarabine and hydroxyurea. Studzinski, G.P., Bhandal, A.K., Brelvi, Z.S. J. Natl. Cancer Inst. (1986) [Pubmed]
  22. Spinal cord penetration of intrathecally administered cytarabine and methotrexate: a quantitative autoradiographic study. Burch, P.A., Grossman, S.A., Reinhard, C.S. J. Natl. Cancer Inst. (1988) [Pubmed]
  23. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Rees, J.K., Gray, R.G., Swirsky, D., Hayhoe, F.G. Lancet (1986) [Pubmed]
  24. Drugs five years later: cytarabine. Kremer, W.B. Ann. Intern. Med. (1975) [Pubmed]
  25. Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy. Champlin, R., Jacobs, A., Gale, R.P., Boccia, R., Elashoff, R., Foon, K., Zighelboim, J. Lancet (1984) [Pubmed]
  26. Continuous infusion or bolus injection in cancer chemotherapy. Carlson, R.W., Sikic, B.I. Ann. Intern. Med. (1983) [Pubmed]
  27. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Wang, Y.Y., Zhou, G.B., Yin, T., Chen, B., Shi, J.Y., Liang, W.X., Jin, X.L., You, J.H., Yang, G., Shen, Z.X., Chen, J., Xiong, S.M., Chen, G.Q., Xu, F., Liu, Y.W., Chen, Z., Chen, S.J. Proc. Natl. Acad. Sci. U.S.A. (2005) [Pubmed]
  28. Cloning and expression of human deoxycytidine kinase cDNA. Chottiner, E.G., Shewach, D.S., Datta, N.S., Ashcraft, E., Gribbin, D., Ginsburg, D., Fox, I.H., Mitchell, B.S. Proc. Natl. Acad. Sci. U.S.A. (1991) [Pubmed]
  29. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Stone, R.M., Berg, D.T., George, S.L., Dodge, R.K., Paciucci, P.A., Schulman, P.P., Lee, E.J., Moore, J.O., Powell, B.L., Baer, M.R., Bloomfield, C.D., Schiffer, C.A. Blood (2001) [Pubmed]
  30. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Karnitz, L.M., Flatten, K.S., Wagner, J.M., Loegering, D., Hackbarth, J.S., Arlander, S.J., Vroman, B.T., Thomas, M.B., Baek, Y.U., Hopkins, K.M., Lieberman, H.B., Chen, J., Cliby, W.A., Kaufmann, S.H. Mol. Pharmacol. (2005) [Pubmed]
  31. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. te Boekhorst, P.A., Löwenberg, B., Sonneveld, P. Leukemia (1994) [Pubmed]
  32. Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Weller, M., Rieger, J., Grimmel, C., Van Meir, E.G., De Tribolet, N., Krajewski, S., Reed, J.C., von Deimling, A., Dichgans, J. Int. J. Cancer (1998) [Pubmed]
  33. Recombinant human interferons alpha, beta and gamma reduce the antiproliferative action of cytarabine in K562 human myeloid leukaemia clonogenic cells. Maurer, H.R., Hassan, H.T., Tsiriyotis, C., Spandidos, D.A. J. Cancer Res. Clin. Oncol. (1992) [Pubmed]
  34. Treatment of acute myelogenous leukemia in children and adults. Weinstein, H.J., Mayer, R.J., Rosenthal, D.S., Camitta, B.M., Coral, F.S., Nathan, D.G., Frei, E. N. Engl. J. Med. (1980) [Pubmed]
  35. Modulation of cell-mediated alloimmunity by BCG. I. Antagonism and potentiation of immunosuppression caused by cytarabine. Murahata, R.I., Mitchell, M.S. J. Natl. Cancer Inst. (1982) [Pubmed]
WikiGenes - Universities